Stuart Lutzker

Dr. Stuart Lutzker is the Chief Medical Officer of ArriVent BioPharma. Dr. Lutzker has extensive drug development experience, having served as Vice President and Head of Oncology, Early Clinical Development at Genentech from 2009-2021. At Genentech, he led the early development of multiple now-approved oncology drugs including Kadcyla, Polivy, Venclexta, Cotellic and Tecentriq. Previously, Dr. Lutzker was a medical oncologist and cancer researcher at the NCI Designated-Cancer Institute of New Jersey, where he split time between patient care and laboratory-based cancer research. He obtained a joint M.D./Ph.D. in Biochemistry from Columbia University College of Physicians and Surgeons. Following his residency and fellowship in Internal Medicine and Medical Oncology at Yale-New Haven Hospital, Dr. Lutzker completed post-doctoral research training in the Department of Molecular Biology at Princeton University. Dr. Lutzker has also served as faculty for the AACR/ASCO Methods in Clinical Cancer Research Workshop in Vail, CO.